Login / Signup

Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.

Anand Ashwin PatelJames J YoonHannah JohnstonMarta B DavidsonRory Michael ShallisEvan C ChenMadelyn BurkartTimothy S OhSunil Girish IyerEllen MadarangChandrasekar MuthiahIyana GrossRaven DeanJoshua KassnerAuro ViswabandyaRafael Madero-MarroquinRaajit K RampalGuru Subramanian Guru MurthyTerrence J BradleyYasmin M AbazaJacqueline S GarciaVikas K GuptaKristen M PettitJohn F CursioOlatoyosi Odenike
Published in: Blood advances (2024)
Progression of myeloproliferative neoplasms (MPNs) to accelerated or blast-phase is associated with poor survival outcomes. Since 2017 there have been several therapies approved for use in acute myeloid leukemia (AML); these therapies have been incorporated into the management of accelerated/blast-phase MPNs (MPN-AP/BP). We performed a multi-center analysis to investigate outcomes of patients diagnosed with MPN-AP/BP in 2017 or later. Two-hundred two patients were identified; median overall survival (OS) was 0.86 years. We also analyzed patients based on first-line treatment; the three most common approaches were intensive chemotherapy (IC) (n=65), DNA methyltransferase inhibitor (DNMTi)-based regimens (n=65), and DNMTi + venetoclax (VEN)-based regimens (n=54). Median OS was not significantly different by treatment type. In addition, we evaluated response by 2017 European LeukemiaNet (ELN) AML criteria and 2012 MPN-BP criteria in an effort to understand the association of response with survival outcomes. We also analyzed outcomes in 65 patients that received allogeneic hematopoietic stem cell transplant (allo-HCT); median OS was 2.30 years from time of allo-HCT. Our study demonstrates that survival amongst patients with MPN-AP/BP is limited in the absence of allo-HCT even in the current era of therapeutics and underscores the urgent need for new agents and approaches.
Keyphrases